AN2 Therapeutics, Inc. (ANTX)
| Market Cap | 160.18M +361.6% |
| Revenue (ttm) | n/a |
| Net Income | -34.55M |
| EPS | -1.11 |
| Shares Out | 36.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 230,556 |
| Open | 4.210 |
| Previous Close | 4.200 |
| Day's Range | 4.150 - 4.655 |
| 52-Week Range | 1.000 - 6.910 |
| Beta | -0.98 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+102.25%) |
| Earnings Date | May 11, 2026 |
About ANTX
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for ANTX stock is "Strong Buy" and the 12-month stock price target is $9.0.
News
AN2 Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Three phase II programs—PV, Mycobacterium abscessus, and Chagas disease—are advancing, with key data readouts expected from late this year through next. Novel oral therapies address significant unmet needs, and additional oncology assets are in early development.
AN2 Therapeutics reports data from two studies of AN2-502998 in Chagas disease
AN2 Therapeutics (ANTX) announced results from two studies evaluating the Company’s oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease caused by infection with the parasite ...
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX) a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry plat...
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ann...
AN2 Therapeutics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
The company is leveraging its boron chemistry platform to expand from infectious diseases into oncology and hematology, with epetraborole advancing into phase II for PV and NTM. Multiple near-term catalysts are expected across a diversified pipeline, including solid tumor and Chagas programs.
AN2 Therapeutics upgraded to Outperform from Market Perform at Leerink
Leerink analyst Joseph Schwartz upgraded AN2 Therapeutics (ANTX) to Outperform from Market Perform with a $9 price target
AN2 Therapeutics reports Q1 EPS (29c), one estimate (23c)
The Company had cash, cash equivalents and investments of $85.3 million at March 31, 2026. In March 2026, AN2 raised gross proceeds of $40.0 million through a private placement, before…
AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...
AN2 Therapeutics Earnings release: Q1 2026
AN2 Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
AN2 Therapeutics Quarterly report: Q1 2026
AN2 Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics derived from its boron chemistry platform, today ann...
AN2 Therapeutics Proxy statement: Proxy filing
AN2 Therapeutics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
AN2 Therapeutics Proxy statement: Proxy filing
AN2 Therapeutics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
AN2 Therapeutics files $300M mixed securities shelf
17:22 EDT AN2 Therapeutics (ANTX) files $300M mixed securities shelf
AN2 Therapeutics Registration statement: Registration filing
AN2 Therapeutics filed a registration statement on April 9, 2026, providing details about a securities offering with the SEC.
AN2 Therapeutics announces initiation of Phase 2 trial of epetraborole
AN2 Therapeutics (ANTX) announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibi...
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla...
AN2 Therapeutics reports Q4 EPS (29c) vs (25c) last year
“Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2’s boron chemistry pipeline and our commitment to addressing s...
AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics der...
AN2 Therapeutics Annual report: Q4 2025
AN2 Therapeutics has published its Q4 2025 annual report on March 17, 2026.
AN2 Therapeutics Earnings release: Q4 2025
AN2 Therapeutics released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.
AN2 Therapeutics Slides: Investor presentation
AN2 Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
AN2 Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Epetraborole is advancing to Phase 2 for polycythemia vera, with dosing set for August and initial data expected in Q4. The oral agent aims to provide stable hematocrit control and may offer disease-modifying potential. Additional pipeline programs include trials for M. abscessus and Chagas disease.
AN2 Therapeutics Announces $40 Million Private Placement Financing
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry pla...
AN2 Therapeutics Transcript: Status update
Epetraborole is being advanced into phase II trials for PV, targeting a major unmet need for oral, red cell-specific therapies. The drug has shown consistent hematocrit control with minimal side effects and could offer rapid, durable benefits for patients inadequately managed by current treatments.